Abiopharma

News list

Bertels Mark E. 🟡 adjusted position in 830 shares (1 derivative) of CORVEL CORP (CRVL) at $57.40 Transaction Date: Apr 22, 2026 | Filing ID: 000010

Full text

News bot April 23, 2026, 11:07 p.m.
🔍 Bertels Mark E. (Executive)

Company: CORVEL CORP (CRVL)

Report Date: 2026-04-22
Transaction Summary:
- Total transactions: 4
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 1,050
- Total shares sold: 1,880
Detailed Transactions and Holdings:
- Acquired 1,050 shares of Common Stock at $39.827 per share (Direct)
  Date: 2026-04-22 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,656.00 | transaction_form_type: 4
- Sold 736 shares of Common Stock at $56.76 per share (Direct)
  Date: 2026-04-22 | Code: F | equity_swap_involved: 0 | shares_owned_after: 2,920.00 | transaction_form_type: 4 | Footnotes: F1
- Sold 94 shares of Common Stock at $57.4 per share (Direct)
  Date: 2026-04-22 | Code: F | equity_swap_involved: 0 | shares_owned_after: 2,826.00 | transaction_form_type: 4 | Footnotes: F1
- Sold 1,050 shares of Non-Qualified Stock Option (right to buy) at $39.827 per share (Derivative)
  Date: 2026-04-22 | Code: M | Expires: 2026-05-06 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
Footnotes:
- F1: Shares delivered in payment of the option exercise price and/or tax liability incident to the option exercise.
- F2: Exercisable as to 25% of shares one year following grant date with the remaining shares exercisable in 36 equal monthly installments thereafter.